Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues    
Service $ 0 $ 16,204
Royalty 2,112 892
Product 11,321 0
Total Revenues 13,433 17,096
Operating Expenses    
Research and development 14,533,862 10,363,253
General and administrative 5,654,018 4,731,054
Sales and marketing 1,073,368 965,713
Total Operating Expenses 21,261,248 16,060,020
Operating Loss (21,247,815) (16,042,924)
Other Income (Expenses)    
Grant income 635,513 155,031
Gain on disposal of fixed assets 293,312 0
Interest income 49,495 112,367
Interest expense (129,799) (126,572)
Other expenses 0 (196,957)
Total Other Income (Expenses) 848,521 (56,131)
Net Loss (20,399,294) (16,099,055)
Net Loss attributable to Non-Controlling Interest 47,179 0
Net Loss attributable to VolitionRx Limited Stockholders (20,352,115) (16,099,055)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments (185,648) (97,981)
Net Comprehensive Loss $ (20,584,942) $ (16,197,036)
Net Loss Per Share - Basic and Diluted $ (0.45) $ (0.41)
Weighted Average Shares Outstanding    
- Basic and Diluted 45,278,847 39,180,369